Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. — Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of these,...

Evidence span

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. — Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of these,...

From Cummings J et al. 2024, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Antibodies, Monoclonal; Amyloid beta-Peptides — BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2024 (cited ≥50×)

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required